SCHEMBL146363

SCHEMBL146363

CC(C)(C)OC(=O)N[C@H]1CN(Cc2ccccc2)C[C@@H]1NC(=O)CCCBr

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NPFFR1 Q9GZQ6 3/20 0.43
NPFFR2 Q9Y5X5 3/20 0.43
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
DRD2 P14416 4/20 0.41
DRD4 P21917 4/20 0.41
DRD3 P35462 4/20 0.41
AKT1 P31749 2/20 0.41
SIGMAR1 Q99720 3/20 0.40
KCNA3 P22001 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
ACE P12821 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
JAK1 P23458 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146364 1.00 KMT2A (0.48) KMT2AL3MBTL1NPFFR1NPFFR2BCHE
SCHEMBL1721452 1.00 KMT2A (0.48) KMT2AL3MBTL1NPFFR1NPFFR2BCHE
SCHEMBL146403 0.88 KMT2A (0.45) KMT2AL3MBTL1NPFFR1NPFFR2BCHE
SCHEMBL459129 0.88 KMT2A (0.45) KMT2AL3MBTL1NPFFR1NPFFR2BCHE
SCHEMBL146402 0.88 KMT2A (0.45) KMT2AL3MBTL1NPFFR1NPFFR2BCHE
SCHEMBL3187533 0.83 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2BCHE
SCHEMBL7835003 0.83 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2BCHE
SCHEMBL7834998 0.83 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2BCHE
SCHEMBL19121559 0.83 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2BCHE
SCHEMBL3187519 0.83 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059014-A1 Compounds for the Treatment of Metabolic Disorders PROSIDION LIMITED (GB) 2012-03-08 US disclosed
US-20120059014-A1 Compounds for the Treatment of Metabolic Disorders PROSIDION LIMITED (GB) 2012-03-08 US disclosed
EP-2406251-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2012-01-18 EP disclosed
WO-2010103334-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059014-A1 Compounds for the Treatment of Metabolic Disorders GPR119, FFAR2, GPBAR1 KMT2A 3204/4885L3MBTL1 4277/4885NPFFR1 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.